Schedule of Components of Deferred Tax Assets (Details) - USD ($) |
Dec. 31, 2025 |
Dec. 31, 2024 |
|---|---|---|
| Restructuring Cost and Reserve [Line Items] | ||
| Net operating loss carryforwards | $ 19,311,000 | $ 16,116,000 |
| Capitalized research and experimental costs | 5,708,000 | 7,836,000 |
| Research and development credit carryforwards | 1,945,000 | 1,945,000 |
| Capitalized start-up expenses | 117,000 | 135,000 |
| Stock-based compensation | 108,000 | 183,000 |
| Other | 660,000 | 309,000 |
| Total deferred tax assets | 27,849,000 | 26,524,000 |
| Valuation allowance | (27,849,000) | (26,524,000) |
| Deferred tax asset | ||
| Eos SENOLYTIXS Inc [Member] | ||
| Restructuring Cost and Reserve [Line Items] | ||
| Net operating loss carryforwards | 330,000 | 77,000 |
| Total deferred tax assets | ||
| Valuation allowance | (64,000) | (19,000) |
| Deferred tax asset | ||
| Net operating loss carryforwards | 83,000 | 19,000 |
| Change in valuation allowance | $ (83,000) | $ (19,000) |
| X | ||||||||||
- Definition Deferred tax assets change valuation allowance. No definition available.
|
| X | ||||||||||
- Definition Deferred tax assets deferred expense capitalized research and development. No definition available.
|
| X | ||||||||||
- Definition Deferred tax assets deferred expense capitalized startup. No definition available.
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|